STA
NBIX icon

Summit Trail Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Summit Trail Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$631K Sell
3,743
-92
-2% -$13.6K 0.01% 1151
2026
Q1 		$505K Buy
3,835
+916
+31% +$122K 0.01% 1163
2025
Q4 		$414K Buy
2,919
+172
+6% +$24.9K 0.01% 1132
2025
Q3 		$386K Buy
2,747
+1,028
+60% +$139K 0.01% 1148
2025
Q2 		$216K Buy
+1,719
New +$197K ﹤0.01% 1033
2018
Q1 		– Sell
-155
Closed -$14K – 1226
2017
Q4 		$14K Buy
+155
New +$10.6K ﹤0.01% 1133

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Summit Trail Advisors's NBIX Position: Q2 2026 in Review

Summit Trail Advisors reduced its Neurocrine Biosciences (NBIX) stake by 2.4% in Q2 2026, selling an estimated $13.6K and leaving 3,743 shares worth $631K. The position accounts for 0.01% of the portfolio, ranked #1151.

Summit Trail Advisors first reported a position in NBIX in Q4 2017 and has held it in 6 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Summit Trail Advisors held 3,743 shares of Neurocrine Biosciences worth $631K as of Q2 2026.
  • Summit Trail Advisors sold 92 Neurocrine Biosciences shares in Q2 2026, an estimated $13.6K.
  • Neurocrine Biosciences made up 0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1151 holding.
  • Summit Trail Advisors first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 6 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.